TrialSignal
Clinical trial intelligence report
A Phase I/II Evaluation of Bromocriptine, Metoprolol and Tamsulosin Combination Therapy in Eyes With Non-Central Diabetic Macular Edema
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03384524
Status
WITHDRAWN
Phase
Phase I/II
Sponsor
Andrew Moshfeghi, MD, MBA
Executive brief
Investment-Ready Snapshot
The BEAT DME Study aimed to evaluate the efficacy of a combination therapy (Bromocriptine, Metoprolol, and Tamsulosin) in treating non-central DME. The study was designed to provide proof of concept for future phase III trials, focusing on a systems pharmacology approach to address complex retinal diseases.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03384524
Indication
Diabetic Macular Edema
Modality
small molecule
Target
Diabetic Macular Edema (DME)
Intervention
Bromocriptine 2.5 MG, Metoprolol 25 MG, Tamsulosin 0.4 MG, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.